Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

LillyDirect Foundayo vs Midi Health

LillyDirect Foundayo
Graded #165

Higher grade

vs+10.800000000000004
Midi Health
Graded #413

Lower grade

The verdict

LillyDirect Foundayo takes it — 67.2/100 to 56.4/100.

LillyDirect Foundayo grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Eli Lilly's manufacturer direct-pay channel for Foundayo (orforglipron), the first oral GLP-1 pill for weight loss.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueLillyDirect Foundayo +27
72
45
Dose & formulationLillyDirect Foundayo +19
59
40
Clinical oversightEven
78
78
Labs & monitoringEven
52
52
FulfillmentLillyDirect Foundayo +2
80
78
Contract termsEven
55
55
LillyDirect Foundayo · left barMidi Health · right bar

The numbers

MetricLillyDirect FoundayoMidi Health
WeighScore67.2/10056.4/100
GradeCC
Scorecard rank#165#413
SemaglutideNot disclosedNot disclosed
TirzepatideNot disclosedNot disclosed
CoverageAll 50 statesAll 50 states
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
LillyDirect Foundayo

Graded #165 · C

Strengths

  • Cheapest legal path to a brand-name GLP-1 in 2026 ($25/mo with savings card for commercial insurance)
  • Direct from manufacturer — no compounding, no third-party reseller
  • Daily oral pill, no injections, no refrigeration
  • Available in all 50 states

Where it loses points

  • Lower mean weight loss vs Wegovy (14.9%) and Zepbound (20.9%) — labeled-dose 11.1% per Foundayo PI
  • Requires existing prescription from a separate prescriber (LillyDirect does not write the prescription)
  • $25 savings card requires commercial insurance — Medicare and Medicaid not eligible
  • Strict empty-stomach 30-minute window may be hard for some patients to follow
Midi Health

Graded #413 · C

Strengths

  • Available in all 50 states
  • Accepts commercial insurance — a differentiator vs cash-pay-only GLP-1 telehealth
  • Menopause + metabolic-health focus suits women where GLP-1 efficacy and weight regulation overlap most
  • Transparent self-pay visit fees ($250 initial, $150 follow-up); GLP-1 can also be billed through commercial insurance (copay + deductible)

Where it loses points

  • Does not accept Medicare, Medicaid, or Medi-Cal
  • GLP-1 is prescribed at clinician discretion within a menopause plan, not guaranteed at intake
  • Menopause-focused — not the right fit for men or younger women whose main goal is weight loss

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard